Steven A Stacker Selected Research

Vascular Endothelial Growth Factor D

1/2018	Emerging Roles for VEGF-D in Human Disease.
1/2017	The fibrinolysis inhibitor α2-antiplasmin restricts lymphatic remodelling and metastasis in a mouse model of cancer.
12/2016	Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
1/2016	VEGF-D promotes pulmonary oedema in hyperoxic acute lung injury.
2/2014	VEGFD regulates blood vascular development by modulating SOX18 activity.
8/2013	Vascular endothelial growth factor-d modulates caliber and function of initial lymphatics in the dermis.
8/2013	Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis.
3/2013	The propeptides of VEGF-D determine heparin binding, receptor heterodimerization, and effects on tumor biology.
3/2013	Tumor location and nature of lymphatic vessels are key determinants of cancer metastasis.
10/2012	Vascular endothelial growth factor-D: signaling mechanisms, biology, and clinical relevance.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Steven A Stacker Research Topics

Disease

40	Neoplasms (Cancer) 01/2021 - 06/2002
19	Neoplasm Metastasis (Metastasis) 01/2017 - 06/2002
15	Lymphatic Metastasis 01/2019 - 08/2004
5	Lymphedema (Milroy Disease) 12/2016 - 11/2002
2	Inflammation (Inflammations) 10/2017 - 02/2005
2	Hypotrichosis 03/2014 - 12/2008
2	Telangiectasis (Telangiectasia) 03/2014 - 12/2008
2	Cardiovascular Diseases (Cardiovascular Disease) 10/2012 - 03/2012
2	Carcinogenesis 01/2010 - 04/2007
2	Carcinoma (Carcinomatosis) 04/2007 - 08/2004
2	Infections 02/2005 - 09/2003
2	Hypoxia (Hypoxemia) 07/2004 - 05/2002
1	Eye Diseases (Eye Disease) 01/2021
1	Lymphangioleiomyomatosis (Lymphangiomyomatosis) 01/2018
1	Animal Disease Models 01/2018
1	Contact Dermatitis (Eczema, Contact) 10/2017
1	Virus Diseases (Viral Diseases) 10/2017
1	Acute Lung Injury 01/2016
1	Hyperoxia 01/2016
1	Wounds and Injuries (Trauma) 08/2013
1	Vascular Remodeling 10/2011
1	Endometrial Neoplasms (Endometrial Cancer) 07/2010
1	Disease Progression 07/2010
1	Intestinal Polyposis (Polyposis, Intestinal) 01/2010
1	Colorectal Neoplasms (Colorectal Cancer) 09/2008
1	Hemorrhage 04/2007
1	Hyperplasia 08/2006
1	Pancreatic Neoplasms (Pancreatic Cancer) 09/2005
1	Respiratory Tract Infections (Respiratory Tract Infection) 02/2005
1	Extranodal Extension 08/2004
1	Prostatic Neoplasms (Prostate Cancer) 08/2004
1	Margins of Excision 08/2004
1	Proteinuria 01/2004
1	Nephrosis 01/2004
1	Membranous Glomerulonephritis (Membranous Nephropathy) 01/2004
1	Atherosclerosis 10/2003
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 03/2003
1	Coronary Artery Disease (Coronary Atherosclerosis) 06/2002
1	Brain Ischemia (Cerebral Ischemia) 06/2002
1	Edema (Dropsy) 06/2002

Drug/Important Bio-Agent (IBA)

29	Vascular Endothelial Growth Factor DIBA 01/2018 - 06/2002
19	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2014 - 05/2002
16	Proteins (Proteins, Gene)FDA Link 01/2021 - 05/2002
16	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2019 - 05/2002
12	Vascular Endothelial Growth Factor CIBA 01/2017 - 09/2003
11	Vascular Endothelial Growth Factor Receptor-3 (Flt 4)IBA 12/2016 - 06/2002
7	Messenger RNA (mRNA)IBA 10/2017 - 05/2002
7	EnzymesIBA 12/2016 - 09/2003
4	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 08/2013 - 05/2002
4	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 03/2013 - 05/2002
3	ProstaglandinsIBA 12/2016 - 02/2012
3	Glycoproteins (Glycoprotein)IBA 12/2016 - 07/2004
2	ChemokinesIBA 01/2019 - 01/2008
2	Indicators and Reagents (Reagents)IBA 03/2013 - 09/2005
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 08/2012 - 02/2012
2	beta CateninIBA 01/2010 - 09/2008
2	Transcription Factors (Transcription Factor)IBA 12/2008 - 07/2004
2	Cell Surface ReceptorsIBA 09/2008 - 12/2005
1	MicroRNAs (MicroRNA)IBA 01/2021
1	Tumor Biomarkers (Tumor Markers)IBA 01/2021
1	CCR10 ReceptorsIBA 01/2019
1	CytokinesIBA 01/2019
1	Chemokine ReceptorsIBA 01/2019
1	Peptide Hydrolases (Proteases)FDA Link 01/2017
1	Fibrinolysin FDA Link 01/2017
1	Antifibrinolytic Agents (Antifibrinolytics)IBA 01/2017
1	Chimeric Antigen ReceptorsIBA 01/2016
1	Oxygen (Dioxygen)IBA 01/2016
1	Immune Checkpoint InhibitorsIBA 01/2016
1	AntibodiesIBA 01/2014
1	Therapeutic UsesIBA 12/2013
1	Bevacizumab (Avastin)FDA Link 06/2013
1	Neutralizing AntibodiesIBA 06/2013
1	Heparin (Liquaemin)FDA LinkGeneric 03/2013
1	Angiogenesis InhibitorsIBA 10/2012
1	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 08/2012
1	MitogensIBA 08/2011
1	Secreted Frizzled-Related ProteinsIBA 09/2008
1	LigandsIBA 09/2008
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2008
1	Monoclonal AntibodiesIBA 01/2008
1	Becaplermin (PDGF-BB)FDA Link 01/2008
1	Matrix Metalloproteinases (MMPs)IBA 04/2007
1	Hyaluronan ReceptorsIBA 09/2005
1	human FLT4 proteinIBA 09/2005
1	Keratins (Keratin)IBA 09/2005
1	Biological ProductsIBA 09/2005
1	Anti-Bacterial Agents (Antibiotics)IBA 02/2005
1	Vascular Endothelial Growth FactorsIBA 07/2004
1	SodiumIBA 01/2004
1	CreatinineIBA 01/2004
1	Puromycin AminonucleosideIBA 01/2004
1	tyrosine receptor (receptor, tyrosine)IBA 09/2003
1	Phosphotransferases (Kinase)IBA 09/2003
1	Tyrosine Kinase InhibitorsIBA 03/2003
1	Epidermal Growth Factor (EGF)IBA 03/2003
1	Gefitinib (Iressa)FDA Link 03/2003

Therapy/Procedure

13	Therapeutics 01/2021 - 08/2004
2	Immunotherapy 01/2016 - 01/2014
1	Surgical Amputation (Amputations) 10/2003